Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Texas MPN Workshop 2020 | Essential thrombocythemia: outcomes, unmet needs, and therapeutic strategies

Prithviraj Bose • 18 Aug 2020
Texas MPN Workshop 2020
Essential Thrombocythemia Myeloproliferative Neoplasms Rare Diseases Hydroxyurea Imetelstat Ropeginterferon alfa-2b Ruxolitinib Venetoclax Vorinostat

Prithviraj Bose, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of disease outcomes, unmet needs and therapeutic strategies of patients with essential thrombocytopenia, including diagnosis, prognosis and management of the disease. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Prithviraj Bose

2:55
Current and emerging treatments for MF: an update from ASH 2023
Prithviraj Bose • 11 Dec 2023
2:21
An update from LIMBER-104: zilurgisertib +/- ruxolitinib in the management of MF-associated anemia
Prithviraj Bose • 11 Dec 2023
3:49
Bezuclastinib in adult patients with non-advanced systemic mastocytosis: initial results from Summit
Prithviraj Bose • 11 Dec 2023
3:30
LIMBER-104: zilurgisertib +/- ruxolitinib in patients with MF-associated anemia
Prithviraj Bose • 6 Sep 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals